M

M.O.L. V600E-driven melanoma.6 Vemurafenib (PLX4032) was the first drug approved for the treatment of BRAFV600E mutant melanoma, showing improved response rates and both progression-free and overall survival NPS-1034 in the clinic.7 Unfortunately, the clinical benefits of vemurafenib are short-lived and the majority of patients relapse within 6C7 months.8 Molecular mechanisms of resistance to MAPK pathway …
Continue reading M

The presence of this enzyme captured our attention because it belongs to the phosphagen kinases, enzymes that reversibly dephosphorylate ATP and phosphorylate a specific substrate, forming an ATP buffer system for the temporally rapid but limited regeneration of ATP when required (reviewed in [15])

The presence of this enzyme captured our attention because it belongs to the phosphagen kinases, enzymes that reversibly dephosphorylate ATP and phosphorylate a specific substrate, forming an ATP buffer system for the temporally rapid but limited regeneration of ATP when required (reviewed in [15]). (sp.). Therefore understanding the factors that allow for the successful infection …
Continue reading The presence of this enzyme captured our attention because it belongs to the phosphagen kinases, enzymes that reversibly dephosphorylate ATP and phosphorylate a specific substrate, forming an ATP buffer system for the temporally rapid but limited regeneration of ATP when required (reviewed in [15])